The plasma supply in Germany

Area of Science:

• Medical Sciences
• Public Health
• Biotechnology

Background:

• Germany aims for self-sufficiency in plasma supply.
• Previous efforts have been made to meet this demand.
• This report details the current state of plasma supply in Germany.

Purpose of the Study:

• To analyze the current status of plasma collection and utilization in Germany.
• To assess trends in therapeutic plasma and source plasma for fractionation.
• To evaluate the supply chain of plasma derivatives.

Main Methods:

• Data collection from the Paul-Ehrlich-Institute.
• Analysis of data on blood and plasma collection and use.
• Review of import/export data for plasma derivatives.

Main Results:

• Therapeutic plasma collection declined slightly but peaked in 2017.
• Plasma for fractionation remained stable at approximately 2 million liters annually.
• Immunoglobulin manufacturing increased, while Factor VIII and IX use persists.
• Import/export activities ensure plasma derivative availability.
• Fibrinogen supplementation and patient blood management reduced therapeutic plasma use.

Conclusions:

• Germany's plasma supply chain is complex, involving domestic collection and international trade.
• Increased immunoglobulin production addresses rising demand for treating immunodeficiencies.
• Despite recombinant alternatives, plasma-derived Factor VIII and IX remain relevant.
• Optimized clinical practices can reduce therapeutic plasma consumption.